Current and future role of biomarkers in Crohn's disease risk assessment and treatment

Clinical and Experimental Gastroenterology

Volumn 4, Issue 1, 2011, Pages 127-140

  Tamboli, Cyrus P ^a   Doman, David B ^b   Patel, Amar ^c  

^a UNIVERSITY OF IOWA   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c Peloton Advantage   (United States)

Author keywords

Biomarkers; Complicated disease; Crohn's disease; Inflammatory bowel disease; Serologic testing

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLIXIMAB; LACTOFERRIN; MESALAZINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN C; OUTER MEMBRANE PROTEIN C ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY TITER; BACTERIAL INFECTION; CARD15 GENE; CROHN DISEASE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FAMILY STUDY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; IMMUNOREACTIVITY; MBL GENE; NOD2 GENE; OLIGOMERIZATION; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 80955139672     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S18187     Document Type: Review

References (124)

1. Gasche C, Scholmerich J, Brynskov J, et al. A simple classifcation of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Infamm Bowel Dis. 2000;6(1): 8-15.
2. Thia K, Sandborn W, Harmsen W, Zinmeister A. The evolution of Crohn's disease (CD) behavior in a population-based cohort [abstract 1135]. Am J Gastroenterol. 2008;103 Suppl 5: S443-S444.
3. Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn's disease at the ileoco-lonic anastomosis after curative surgery. Gut. 1984;25(6):665-672.
4. Silverstein MD, Loftus E V, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117(1):49-57.
5. Lichtenstein GR, Hanauer SB, Sandborn WJ; For the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104(2): 465-483.
6. Carter MJ, Lobo AJ, Travis S P. Guidelines for the management of Inflammatory bowel disease in adults. Gut. 2004; 53 Suppl 5: 6-66.
7. Hanauer SB. Positioning biologic agents in the treatment of Crohn's disease. Infamm Bowel Dis. 2009;15(10):1570-1582.
8. Kane S V, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. Systematic review: the effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 2002;16(8):1509-1517.
9. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123(2):132-142.
10. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77(4 Pt 2):847-869.
11. Vermeire S, Van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25(1):3-12.
12. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for infam-matory bowel disease: a population-based study. Gastroenterology. 2001;121(2):255-260.
13. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54(2):237-241.
14. Dhillon SL, Loftus E V, Tremaine WJ. The natural history of surgery for Crohn's disease in a population-based cohort from Olmsted County, Minnesota [abstract 825]. Am J Gastroenterol. 2005; 100 Suppl: S305.
15. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Infamm Bowel Dis. 2002;8(4):244-250.
16. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105(2):289-297.
17. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995;30(7):699-706.
18. D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol. 2010;7(2):86-92.
19. Schreiber S, Reinisch W, Colombel JF, et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM [abstract 985]. Gastroenterology. 2007; 132 Suppl 1: A147.
20. Sandborn WJ, Colombel J F, Panes J, Scholmerich J, McConnell J, Schreiber S. Higher remission and maintenance of response rates with subcutaneous monthly certolizumab pegol in patients with recent-onset Crohn's disease: data from PRECiSE 2 [abstract 1109]. Am J Gastroenterol. 2006;101:S454-S455.
21. Sandborn WJ, Rutgeerts P, Reinisch W, et al. SONIC: a randomized, double-blind, controlled trial comparing infiximab and infiximab plus azathioprine in patients with Crohn's disease naive to immuno-modulators and biologic therapy [late-breaking abstract 29]. Am J Gastroenterol. 2008;103 Suppl 1: S423.
22. D'Haens G, Baert F, Van Assche G, et al. Early combined immunosup-pression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371(9613): 660-667.
23. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterolog y. 2000;119(4):895-902.
24. Ollendorf DA, Lidsky L. Infiximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther. 2006;13(6):502-506.
25. Bodger K. Economic implications of biological therapies for Crohn's disease: review of infliximab. Pharmacoeconomics. 2005;23(9): 875-888.
26. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130(3):650-656.
27. Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology. 1996;110(2):424-431.
28. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterolog y. 1994;106(3):643-648.
29. Sands BE, Arsenault JE, Rosen MJ, et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol. 2003;98(12):2712-2718.
30. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classifcation of Inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 Suppl A: 5-36.
31. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135(4):1106-1113.
32. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg. 2000;231(1):38-45.
33. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430-1438.
34. Romberg-Camps MJ, Dagnelie PC, Kester AD, et al. Infuence of phenotype at diagnosis and of other potential prognostic factors on the course of Inflammatory bowel disease. Am J Gastroenterol. 2009;104(2):371-383.
35. Dotan I. Disease behavior in adult patients: are there predictors for stricture or fstula formation? Dig Dis. 2009;27(3):206-211.
36. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal infam-mation in Inflammatory bowel diseases: performance of fecal lactofer-rin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103(1):162-169.
37. Sipponen T, Savilahti E, Kärkkäinen P, et al. Fecal calprotectin, lacto-ferrin, and endoscopic disease activity in monitoring anti- TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008;14(10): 1392-1398.
38. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357(3):228-238.
39. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of infammation in Inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57(11): 1518-1523.
40. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Infamm Bowel Dis. 2008;14(1):32-39.
41. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic fndings. Infamm Bowel Dis. 2008;14(1):40-46.
42. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with Inflammatory bowel disease. J Allergy Clin Immunol. 1990;86(2):202-210.
43. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ. 1988;297(6656): 1105-1106.
44. Peyrin-Biroulet L, Standaert-Vitse A, Branche J, Chamaillard M. IBD serological panels: facts and perspectives. Infamm Bowel Dis. 2007;13(12):1561-1566.
45. Papo M, Quer JC, Pastor RM, et al. Antineutrophil cytoplasmic antibodies in relatives of patients with Inflammatory bowel disease. Am J Gastroenterol. 1996;91(8):1512-1515.
46. Folwaczny C, Noehl N, Endres S P, Loeschke K, Fricke H. Anti-neutrophil and pancreatic autoantibodies in frst-degree relatives of patients with Inflammatory bowel disease. Scand J Gastroenterol. 1998;33(5):523-528.
47. Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease defne a clinical subgroup. Gastroenterolog y. 1996;110(6):1810-1819.
48. Sendid B, Quinton JF, Charrier G, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol. 1998;93(8):1306-1310.
49. Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces cerevi-siae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Infamm Bowel Dis. 2001;7(1):8-15.
50. Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology. 2000;119(1):23-31.
51. Halfvarson J, Standaert-Vitse A, Jarnerot G, et al. Anti-Saccharomyces cerevisiae antibodies in twins with Inflammatory bowel disease. Gut. 2005;54(9):1237-1243.
52. Seibold F, Konrad A, Flogerzi B, et al. Genetic variants of the mannan-binding lectin are associated with immune reactivity to mannans in Crohn's disease. Gastroenterolog y. 2004;127(4):1076-1084.
53. Muller S, Schaffer T, Flogerzi B, et al. Mannan-binding lectin defciency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogens. Gut. 2010;59(11):1493-1500.
54. Mei L, Targan SR, Landers CJ, et al. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterolog y. 2006;130(4):1078-1085.
55. Torok H P, Glas J, Hollay HC, et al. Serum antibodies in frst-degree relatives of patients with IBD: a marker of disease susceptibility? A follow-up pilot-study after 7 years. Digestion. 2005;72(2-3):119-123.
56. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of Inflammatory bowel disease. Gut. 2005;54(9):1232-1236.
57. Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterolog y. 2006;130(6):1764-1775.
58. Berlin T, Zandman-Goddard G, Blank M, et al. Autoantibodies in nonautoimmune individuals during infections. Ann N Y Acad Sci. 2007; 1108:584-593.
59. Condino AA, Hoffenberg EJ, Accurso F, et al. Frequency of ASCA seropositivity in children with cystic fbrosis. J Pediatr Gastroenterol Nurs. 2005;41(1):23-26.
60. Lachenal F, Nkana K, Nove-Josserand R, Fabien N, Durieu I. Prevalence and clinical signifcance of auto-antibodies in adults with cystic fbrosis. Eur Respir J. 2009;34(5):1079-1085.
61. Makharia GK, Sachdev V, Gupta R, Lal S, Pandey RM. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis. Dig Dis Sci. 2007;52(1):33-39.
62. Granito A, Zauli D, Muratori P, et al. Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. Aliment Pharmacol Ther. 2005;21(7): 881-887.
63. Sakly W, Mankai A, Sakly N, et al. Anti-Saccharomyces cerevisiae antibodies are frequent in type 1 diabetes. Endocr Pathol. 2010;21(2): 108-114.
64. Muratori P, Muratori L, Guidi M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol. 2003;132(3):473-476.
65. Riente L, Chimenti D, Pratesi F, et al. Antibodies to tissue transglu-taminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. J Rheumatol. 2004;31(5):920-924.
66. Sendid B, Colombel J F, Jacquinot PM, et al. Specifc antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol. 1996;3(2):219-226.
67. Standaert-Vitse A, Sendid B, Joossens M, et al. Candida albicans colonization and ASCA in familial Crohn's disease. Am J Gastroenterol. 2009;104(7):1745-1753.
68. Anand BS. Diagnosis of gastrointestinal tuberculosis. Trop Gastroenterol. 1994;15(4):179-185.
69. Hoffman IE, Demetter P, Peeters M, et al. Anti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis. 2003;62(5): 455-459.
70. Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology. 1997;25(5): 1105-1107.
71. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterolog y. 2004;126(2):414-424.
72. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99(12):2376-2384.
73. Papadakis KA, Yang H, Ippoliti A, et al. Anti-fagellin (CBir1) phe-notypic and genetic Crohn's disease associations. Infamm Bowel Dis. 2007;13(5):524-530.
74. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101(2):360-367.
75. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;6(10):1105-1111.
76. Ippoliti A, Devlin S, Mei L, et al. Combination of innate and adaptive immune alterations increased the likelihood of fbrostenosis in Crohn's disease. Infamm Bowel Dis. 2010;16(8):1279-1285.
77. Sandborn WJ, Loftus EV, Colombel J F, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Infamm Bowel Dis. 2001;7(3):192-201.
78. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in Inflammatory bowel disease. Am J Gastroenterol. 2001;96(3):730-734.
79. Klebl FH, Bataille F, Hofstadter F, Herfarth H, Scholmerich J, Rogler G. Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease. Int J Colorectal Dis. 2004;19(4):319-324.
80. Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineu-trophil cytoplasmic antibodies in Inflammatory bowel disease. Am J Gastroenterol. 2006;101(10):2410-2422.
81. Solberg IC, Lygren I, Cvancarova M, et al. Predictive value of serologic markers in a population-based Norwegian cohort with Inflammatory bowel disease. Infamm Bowel Dis. 2009;15(3):406-414.
82. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in Inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56(10):1394-1403.
83. Ashorn S, Honkanen T, Kolho KL, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with Inflammatory bowel disease. Infamm Bowel Dis. 2009;15(2):199-205.
84. Benor S, Russell GH, Silver M, Israel EJ, Yuan Q, Winter HS. Shortcomings of the Inflammatory Bowel Disease Serology 7 panel. Pediatrics. 2010;125(6):1230-1236.
85. Morganstern JA, Shakir T, Chawla A. Is CBir1 a predictor of pediatric Inflammatory bowel disease? [abstract 2]. J Pediatr Gastroenterol Nutr. 2007;45:E1.
86. Rashid F, Bechtold ML, Puli SR, Bragg JD. Utility of IBD serology tests: experience of an academic medical center. The Internet J Gastroenterol. 2011:10(1).
87. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterolog y. 2002;123(3):689-699.
88. Lodes MJ, Cong Y, Elson CO, et al. Bacterial fagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113(9):1296-1306.
89. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 fagellin defne a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005;128(7):2020-2028.
90. Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribio-side and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology. 2006;131(2):366-378.
91. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology. 2002;122(5):1242-1247.
92. Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004;53(8):1117-1122.
93. Klebl FH, Bataille F, Bertea CR, et al. Association of perinuclear anti-neutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classifcation subtypes of Crohn's disease. Infamm Bowel Dis. 2003;9(5):302-307.
94. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifes Crohn's disease into immuno-logically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47(4):487-496.
95. Fleshner PR, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchi-tis after ileal pouch-anal anastomosis. Gut. 2001;49(5):671-677.
96. Fleshner P, Ippoliti A, Dubinsky M, et al. Both preoperative peri-nuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients infuence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008;6(5):561-568.
97. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fbrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002;123(3):679-688.
98. Brant SR, Picco MF, Achkar J P, et al. Defning complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Infamm Bowel Dis. 2003;9(5):281-289.
99. Schoepfer AM, Schaffer T, Mueller S, et al. Phenotypic associations of Crohn's disease with antibodies to fagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort. Infamm Bowel Dis. 2009;15(9):1358-1367.
100. Lesage S, Zouali H, Cezard J P, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with infam-matory bowel disease. Am J Hum Genet. 2002;70(4):845-857.
101. Ippoliti AF, Devlin S, Yang H, et al. The relationship between abnormal innate and adaptive immune function and fbrostenosis in Crohn's disease patients [abstract 127]. Gastroenterology. 2006;130:A24-A25.
102. Hugot J P, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411(6837):599-603.
103. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411(6837):603-606.
104. Franke A, McGovern D P, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confrmed Crohn's disease susceptibility loci. Nat Genet. 2010;42(12):1118-1125.
105. Economou M, Trikalinos TA, Loizou KT, Tsianos E V, Ioannidis J P. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol. 2004;99(12):2393-2404.
106. Yazdanyar S, Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Penetrance of NOD2/CARD15 genetic variants in the general population. CMAJ. 2010;182(7):661-665.
107. Helio T, Halme L, Lappalainen M, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut. 2003;52(4):558-562.
108. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classifcation of the clinical manifestations of Crohn's disease. Gastroenterology. 2002;122(4):854-866.
109. Weersma RK, Stokkers PC, van Bodegraven AA, et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut. 2009;58(3):388-395.
110. Dassopoulos T, Frangakis C, Cruz-Correa M, et al. Antibodies to Saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Infamm Bowel Dis. 2007;13(2):143-151.
111. Devlin SM, Yang H, Ippoliti A, et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterolog y. 2007;132(2):576-586.
112. Joossens M, Van Steen K, Branche J, et al. Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease. Infamm Bowel Dis. 2010;16(1):58-67.
113. Takedatsu H, Taylor KD, Mei L, et al. Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation. Gut. 2009;58(1):60-67.
114. Walker LJ, Aldhous MC, Drummond HE, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol. 2004;135(3):490-496.
115. Lichtenstein GR, Barken DM, Eggleston L, et al. A novel algorithm-based approach using clinical parameters, genetic and serological markers to effectively predict aggressive disease behavior in patients with Crohn's disease [abstract 207]. Presented at Digestive Disease Week; New Orleans, LA; May 1-6, 2010.
116. Arnott ID, McNeill G, Satsangi J. An analysis of factors infuencing short-term and sustained response to infiximab treatment for Crohn's disease. Aliment Pharmacol Ther. 2003;17(12):1451-1457.
117. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infiximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4(10):1248-1254.
118. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996;71(5):431-436.
119. Mow WS, Landers CJ, Steinhart AH, et al. High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study. Dig Dis Sci. 2004;49(7-8): 1280-1286.
120. Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol. 2002;97(6):1458-1462.
121. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infiximab in patients with ulcerative colitis. Infamm Bowel Dis. 2007;13(2):123-128.
122. Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S. Predictive model for the outcome of infiximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Infamm Bowel Dis. 2007;13(4):372-379.
123. Dubinsky MC, Mei L, Friedman M, et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric Inflammatory bowel disease. Infamm Bowel Dis. 2009;16(8): 1357-1366.
124. Devlin SM, Dubinsky MC. Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD. Infamm Bowel Dis. 2008;14(1):125-128.